US Pharma MarketingRoivant’s road to a potential blockbuster begins with Lisraya FDA approval
FDA approves Roivant Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals:…
The FDA approved Roivant’s dermatomyositis drug brepocitinib on Wednesday, the first major regulatory nod that could usher in a multibillion revenue stream for the hub-and-spoke pharma.
The drug, marketed as Lisraya, is the first oral ...
Source: Endpoints News